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Household transmission of Neisseria meningitidis in the 
African meningitis belt: a longitudinal cohort study
MenAfriCar Consortium*
Summary
Background Information on transmission of meningococcal infection in the African meningitis belt is scarce. We aimed 
to describe transmission patterns of Neisseria meningitidis (meningococcus) in households in the African meningitis belt.
Methods Cross-sectional carriage surveys were done in seven African meningitis belt countries (Chad, Ethiopia, Ghana, 
Mali, Niger, Nigeria, and Senegal) between Aug 1, 2010, and Oct 15, 2012. Meningococcal carriers identiﬁ ed in these 
surveys and all available peop le in their households were recruited into this longitudinal cohort study. We took pharyngeal 
swabs at ﬁ rst visit and took further swabs twice a month for 2 months and then monthly for a further 4 months. We used 
conventional bacteriological and molecular techniques to identify and characterise meningococci. We estimated the rates 
of carriage acquisition and recovery using a multi-state Markov model.
Findings Meningococci were isolated from 241 (25%) of 980 members of 133 households in which a carrier had been 
identiﬁ ed in the cross-sectional survey or at the ﬁ rst household visit. Carriage was detected subsequently in another 
household member who was not an index carrier in 75 households. Transmission within a household, suggested by 
detection of a further carrier with the same strain as the index carrier, was found in 52 of these 75 households. Children 
younger than 5 years were the group that most frequently acquired carriage from other household members. The overall 
individual acquisition rate was 2·4% (95% CI 1·6–4·0) per month, varying by age and household carriage status. The 
mean duration of carriage was 3·4 months (95% CI 2·7–4·4).
Interpretation In the African meningitis belt, transmission of meningococci within households is important, 
particularly for young children, and periods of carriage are usually of short duration.
Funding Bill & Melinda Gates Foundation, Wellcome Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. 
Introduction
The vast majority of infections with Neisseria meningitidis 
(meningococcus) result in asymptomatic or mildly 
symptomatic pharyngeal carriage rather than invasive 
disease. Study of carriage is therefore essential to under-
stand patterns of infection in diﬀ erent epidemiological 
situations and to develop evidence-based strategies for 
vaccination. Data for vaccination strategies are parti-
cularly important because of the availability of protein-
polysaccharide conjugate vaccines, which, unlike plain 
polysaccharide vaccines,1 are able to reduce carriage and 
thus transmission, generating herd protection.2
Many cross-sectional studies of meningococcal carriage 
have been done in high-income countries,3 but few 
studies have been undertaken of pathways of trans-
mission. Meningococci are transmitted from the pharynx 
of one person to another via respiratory and throat 
secretions. Military studies have emphasised the 
importance of close personal contact in carriage 
acquisition.3–7 In the UK, rapid acquisition of meningo-
coccal carriage was reported in university students at the 
start of term and was associated with smoking, drinking, 
and intimate kissing.4,5 Carriage prevalence in contacts of 
people with meningococcal disease is higher than in the 
general population,6 but we are aware of only two 
longitudinal household carriage studies done in high-
income countries.7,8
Even less is known about the pattern of transmission of 
meningococcal infection in the African meningitis belt, 
where epidemics of meningococcal disease continue to 
occur.9 In a 2007 Review10 we showed that in several 
surveys, carriage peaked in older children and young 
adults. Subsequent large cross-sectional carriage surveys 
in Africa have shown carriage to be consistently highest 
in children aged 5–14 years,11 with increased carriage 
rates in close contacts of people with the disease, 
suggesting that transmission within households is 
important.12 The few longitudinal studies of carriage 
undertaken in the African meningitis belt have generally 
reported changes in trends over time at a population 
level rather than at the individual level, and thus were 
unable to estimate acquisition and the duration of 
carriage.13–17 We are aware of only one previous study 
that has investigated patterns of transmission of 
meningococci within households in the African 
meningitis belt.18 A 1976 study in northern Nigeria that 
took place over 11 months found that the duration of 
carriage was approximately 3 months for all meningococci 
and 1 month for serogroup A meningo cocci. Children 
younger than 10 years were identiﬁ ed as ﬁ rst carriers in a 
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household signiﬁ cantly more frequently than were 
adults, and men were more likely to introduce 
meningococci into a household than were women.
Because of the paucity of information on meningococcal 
carriage in the African meningitis belt, members 
of the African Meningococcal Carriage Consortium 
(MenAfriCar)19 undertook a series of carriage surveys 
aiming to better understand patterns of meningococcal 
carriage and the impact of a new serogroup A meningo-
coccal conjugate vaccine, MenAfriVac (Serum Institute of 
India PVT, Pune, India).20 From Aug 1, 2010, to July 8, 2012, 
the consortium did 20 cross-sectional carriage surveys in 
seven African meningitis belt countries involving the 
collection of more than 48 000 pharyngeal swabs.11 During 
these surveys, households in which a meningococcal 
carrier was identiﬁ ed were recruited for a longitudinal 
study of household meningococcal trans mission; here we 
report the results of this longitudinal study.
Methods
Cross-sectional carriage surveys
The cross-sectional carriage surveys were conducted in 
seven countries in the African meningitis belt (Chad, 
Ethiopia, Ghana, Mali, Niger, Nigeria, and Senegal) in 
partnership with a national research institution, during 
the rainy season of 2010 (August to December), the rainy 
season of 2011 (July to November), and the dry season of 
2012 (February to July). Details of the survey methods 
have been published previously.19 The sampling frame 
used was either an updated, ongoing demographic 
surveillance system (DSS) in sites where a DSS existed 
or a household census undertaken speciﬁ cally for the 
project. Study households were selected by simple 
random sampling from the DSS or census. Within 
selected households, individuals stratiﬁ ed by age group 
(<1 years, 1–4 years, 5–14 years, 15–29 years, and 30 years 
or older) were randomly selected until the required 
sample size had been reached (surveys varied in target 
size from 2000–6000). Five surveys undertaken in Chad, 
Mali, and Niger were conducted after the introduction of 
vaccination with MenAfriVac in participants aged 
1–29 years. The MenAfriCar studies were registered with 
ClinicalTrials.gov, number NCT01119482. 
Household surveys
Longitudinal household surveys were triggered by the 
identiﬁ cation of a putative carrier during a cross-sectional 
survey. Within 4 weeks of the identiﬁ cation of a carrier, all 
members of the carrier’s household were invited to 
participate in the follow-up study. Swabs (sterile, dacron-
tipped swabs with plastic shafts) of both the posterior 
pharynx and tonsils21 were collected from all consenting 
members of the household at the ﬁ rst visit and 
subsequently twice a month for 2 months and then 
monthly for a further 4 months up to a maximum of nine 
swabs per person. A questionnaire that asked about the 
characteristics of the household was administered to the 
head of the household and a detailed socioeconomic 
questionnaire was administered to individual parti cipants. 
Height and weight of each household contact older than 
6 months of age were measured, and a pharyngeal swab 
and a 5 mL blood sample were obtained. On subsequent 
visits, pharyngeal swabs were taken and a short 
questionnaire was administered to obtain infor mation on 
risk factors, including MenAfriVac immunisation status, 
which might have changed since the last visit.
Identiﬁ cation of a carrier at the study site depended 
upon conventional microbiology and serogrouping with 
an agglutination assay.19 However, conﬁ rmatory tests 
performed using molecular methods undertaken at the 
Department of Zoology at the University of Oxford (UK) 
resulted in some isolates being reclassiﬁ ed as capsule-
Research in context
Evidence before this study
We searched PubMed with the terms ([meningococcal OR 
Neisseria] AND [community OR household] AND carriage AND 
Africa) with no date or language restrictions up to Oct 21, 2015, 
and searched for early government reports from African 
meningitis belt countries in the personal archive of BG to 
identify longitudinal studies of meningococcal carriage in 
African households. Only one relevant study was identiﬁ ed, 
which took place in 1976 in northern Nigeria over the course of 
11 months. This study followed over 500 residents, estimating 
the duration of carriage to be around 3 months. Expanding our 
search to any location, we identiﬁ ed only two further 
longitudinal household carriage studies, both from the USA.
Added value of this study
To our knowledge this is the ﬁ rst multicentre and 
multicountry longitudinal meningococcal carriage study. 
We address an important knowledge gap by describing the 
duration and acquisition of meningococci and patterns 
of transmission in households across the African 
meningitis belt. 
Implications of all the available evidence
Results from this, and the previous study in Nigeria, show 
that the duration of meningococcal carriage is shorter in the 
African meningitis belt than in high-income countries. 
Within-household acquisition is important, with children 
aged 5–14 years being a common source of transmission, 
particularly to younger siblings. Chemoprophylaxis to 
household contacts of an individual with meningococcal 
disease, a public health intervention not widely used in 
Africa, should be emphasised as an additional meningitis 
prevention tool. 
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null organisms and others being not conﬁ rmed as 
meningococci; thus some households were recruited in 
whom no meningococcal carrier was identiﬁ ed on 
conﬁ rmatory testing. These households formed a 
control group.
The study was approved by the ethics committee of the 
London School of Hygiene and Tropical Medicine and by 
the relevant authorities in each African country 
(appendix). The head of the household or another 
responsible adult gave verbal informed consent for the 
household to be included in the study. Each individual 
recruited within that household gave written informed 
consent (signature or thumbprint); a parent or guardian 
gave written consent for children younger than 18 years, 
with children older than 12 years additionally asked to 
give written assent.
Laboratory procedures
Pharyngeal swabs were plated directly onto modiﬁ ed 
Thayer-Martin agar plates in the ﬁ eld and taken to the 
laboratory within 6 h of collection where they were 
incubated for 24–48 h at 37°C in 5% CO2. Suspected 
N meningitidis colonies identiﬁ ed on the plates were 
subcultured onto blood agar plates and tested using an 
oxidase test, followed by a Gram stain. All oxidase-
positive, Gram-negative diplococci underwent bio-
chemical testing and those identiﬁ ed as N meningitidis on 
these tests underwent slide-agglutination sero grouping 
using antisera for serogroups A, W, X and Y, which we 
had identiﬁ ed a priori as the likely most prevalent 
serogroups. All non-agglutinated strains were classiﬁ ed 
as non-groupable (NG) by this method.
To conﬁ rm the identity of Neisseria spp identiﬁ ed by 
culture techniques, an aliquot of boiled suspensions of 
Gram-negative oxidase-positive bacteria was sent to the 
University of Oxford for molecular analysis as described 
previously.19 Ampliﬁ cation and sequencing of the rplF 
gene was used to conﬁ rm the presence of, and 
to diﬀ erentiate between, Neisseria spp.22 Conﬁ rmed 
N meningitidis were further characterised by genogroup 
(including capsule null [cnl] 23) and porA genotype. 
Statistical analysis
There were few studies on the rate of meningococcal 
acquisition in household contacts in Africa to assist in the 
design of the household studies, but informed 
presumption was that the household acquisition rate 
would be around 1% per month.18 We decided 
pragmatically that 25 households per survey in rural and 
urban areas would be the maximum number that the ﬁ eld 
teams had the capacity to recruit and follow-up. Initially, 
restriction of recruitment to households of a serogroup A 
carrier was planned, but because of the paucity of carriers 
of this serogroup,11 recruitment was expanded to include 
carriage of other capsulated meningococci.
Acquisition of carriage was initially deﬁ ned as a newly 
identiﬁ ed episode of carriage, preceded by at least one 
negative swab (appendix). We estimated the rates of 
carriage acquisition (λ) and loss (ν) using a two-state 
(infected and uninfected) hidden Markov model, 
implemented using the MSM package in R version 
3.2.1.24 We estimated the mean duration of carriage as 
1/ν. The observations were assumed to be subject to 
misclassiﬁ cation error and so we used the same statistical 
package to estimate sensitivity and speciﬁ city of 
swabbing. We investigated covariates aﬀ ecting transition 
intensities, including age, sex and whether an individual 
was from a household with at least one index carrier. We 
compared diﬀ erent (nested) models with and without 
covariates using the likelihood ratio statistic. Data from 
individuals with only one swab through the course of the 
study were uninformative and thus we excluded these 
individuals from this analysis. We managed data using 
the TeleForm system version 10.4.1 (Autonomy, 
See Online for appendix
2010 
(HH1)
2011 
(HH2)
2012 
(HH3)
Total Index carrier of Neisseria 
meningitidis in household
Yes No
Chad 0 20* 0* 20 14 6
Ethiopia 20 15 10 45 34 11
Ghana 0 13 9 22 18 4
Mali 22 10* 0* 32 9 23
Niger 40 20* 0* 60 54 6
Nigeria 0 0 0 0 0 0
Senegal 0 5 0 5 4 1
Total 82 83 19 184 133 51
HH=household. *Indicates surveys performed after or during the introduction of 
MenAfriVac.
 Table 1: Household studies by country and survey year and presence of 
an index carrier of Neisseria meningitidis after full molecular 
characterisation
218 households recruited with 
 an initial N meningitidis 
 carrier at visit 0
184 households participated 
 (1351 individuals)
51 households (of 371 people) did not have 
a confirmed index carrier on molecular 
analysis (control group)
133 households (241 of 980 people) had 
confirmed index carrier on molecular 
analysis
34 were excluded
 10 had missing DNA from putative carriage isolates
 16 due to poor data quality 
 3 only Neisseria lactamica carriers 
 1 due to only one household recruited in that country
 4 only one individual per household recruited
Figure 1: Study proﬁ le
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Cambridge UK),19 with a separate database module to 
link the main study database with genetic laboratory 
results from the Oxford Bacterial Isolate Genome 
Sequence (BIGS) database.25 We used Stata version 12.0 
for data cleaning and descriptive analyses.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
218 households were recruited to the study (ﬁ gure 1). 
1351 individuals from 184 households participated in the 
study (appendix); no data were available for Nigeria. 
633 individuals (47%) reported that they had not received 
a meningitis vaccine in the last 3 years, 502 (37%) 
reported that they had recently been vaccinated (224 of 
whom were vaccinated again during the study), and 
216 (16%) individuals reported being new vaccine 
recipients during the course of the study. Most reports of 
previous vaccination (89%) were recorded in Chad, Mali, 
and Niger, where mass vaccination with MenAfriVac in 
participants aged 1–29 years was being undertaken at the 
time of the follow-up study.
133 (72%) of the 184 households had a conﬁ rmed index 
carrier at visit 0 or visit 1 or both (980 people in 
household), leaving 51 (28%) households (of 371 people) 
in which the initial report of isolation of N meningitidis 
was not conﬁ rmed on molecular analysis (table 1); these 
households formed the control group that was used to 
study external acquisitions.
241 (25%) individuals in the 133 households were 
index carriers (carrier at visit 0 or 1). 60 households 
contained more than one index carrier (range one to 
eight carriers per household). The median age of index 
carriers was 12 years (IQR 8–23 years) and 133 (55%) 
were male. cnl was the most common genogroup 
identiﬁ ed, followed by genogroup W (ﬁ gure 2). 
69 individuals were carriers at both the cross-sectional 
recruitment visit (visit 0) and ﬁ rst household visit 
(visit 1). Among these, 56 (81%) carried strains with the 
same genogroup and porA alleles at both visits, and only 
three (4%) carried deﬁ nitively diﬀ erent strains between 
visit 0 and visit 1.
During the course of the 6 month follow-up period, 
9809 swabs were obtained from the 1351 participants; 
63% individuals provided eight or nine swabs and 86% of 
individuals provided at least ﬁ ve swabs. The median 
number of swabs obtained per participant was eight 
(IQR seven to nine). This number was similar in 
households with and without an index carrier. The 
median duration of follow-up from ﬁ rst to last swab was 
6·1 months (IQR 5·2–6·6). None of the participants who 
became a carrier during the period of follow-up are 
known to have developed meningitis. None of the study 
sites reported an outbreak of meningitis during the 
longitudinal follow-up period.
152 (21%) of 739 individuals living with index carriers 
became a carrier during the course of follow-up. 
Individuals acquiring carriage were mainly children: 
45 (30%) children aged 0–4 years, 52 (34%) children aged 
5–14 years, 31 (20%) adults aged 15–29 years, and 24 (16%) 
adults aged 30 years and older. Subsequent carriers were 
detected in 75 (56%) of 133 households.
Acquisition rate per 
month (%)
Duration of carriage 
(months)
Overall 2·4% (1·6–4·0) 3·4 (2·7–4·4)
Age group
0–4 year olds
Index 7·1% (4·3–11·9) 2·0 (1·3–3·2)
Control 1·5% (0·4–5·1) 1·7 (0·8–3·6)
5–14 year olds
Index 4·9% (2·9–8·0) 3·8 (2·8–5·0)
Control 1·0% (0·3–3·5) 3·1 (1·6–5·9)
15–29 year olds
Index 3·5% (1·9–6·3) 5·2 (3·5–7·7)
Control 0·7% (0·2–2·6) 4·2 (2·0–8·9)
30 years and older
Index 1·6 (0·7–3·8) 4·4 (2·9–6·6)
Control 0·3% (0·1–1·4) 3·6 (1·6–7·7)
Data in parentheses are 95% CI.
 Table 2: Rates of acquisition and duration of carriage estimated using a 
hidden Markov model, with age group and household type included as 
covariates
B (n=2)
A (n=9)
ND (n=11)
W (n=76)
C (n=2)
W/Y (n=1)
X (n=6)
Y (n=23)
cnl (n=110)
B/W (n=1)
Figure 2: Genogroup of meningococci carried by 241 index carriers
cnl=capsule null meningococci. ND=not determined.
Articles
www.thelancet.com/lancetgh   Vol 4   December 2016 e993
Among the 371 people in 51 households without an 
index carrier, 35 (9%) people in 17 households became a 
carrier during the course of the study. 25 individuals 
were identiﬁ ed as the ﬁ rst carrier in these households (ie, 
the person introducing the strain into the household), of 
whom 15 (60%) were female and ten (40%) male; three 
(12%) individuals were younger than 5 years, 13 (52%) 
aged 5–14 years, six (24%) aged 15–29 years, and three 
(12%) aged 30 years and older.
The overall acquisition rate and duration of carriage, 
together with mis classi ﬁ cation probabilities, were 
estimated using a hidden Markov model. The best ﬁ tting 
model was one that included age group and household 
index status as covariates. The overall estimated 
acquisition rate of carriage in this model was 2·4% per 
month (95% CI 1·6–4·0; table 2). Acquisition rates were 
highest in the youngest children and lowest among older 
adults (table 2). Acquisition rates were estimated to be 
between four-times and ﬁ ve-times higher in each age 
group among households with an index carrier than in 
those without an index carrier. The estimated mean 
duration of carriage was 3·4 months overall (95% CI 
2·7–4·4) and was lowest in children under 5 years of age 
(table 2).
Only 20 individuals had a positive swab on six or more 
occasions: six individuals with group W, six with cnl, four 
with group Y, one with group B, and three mixed carriers. 
The estimated duration of carriage in these 20 individuals 
was 5·8 months (assuming that a single negative swab 
bordered by positive swabs was a false negative).
The speciﬁ city of swabbing in the full dataset was 
estimated to be very high at 99·2% (95% CI 98·5–99·6), 
whereas the sensitivity of swabbing was estimated to be 
much lower at 57·8% (53·5–62·0).
Data were analysed further according to the strain type 
(genogroup and porA) of meningococci within the 
household. Among the 75 households with both an index 
carrier and later acquisitions, the index strain was 
acquired by another household member in 52 households, 
and a similar strain (with incomplete typing) was 
acquired in a further ﬁ ve households. Where direct 
family relationships could be elucidated in these 
transmission events, sibling to sibling transmission was 
most common (27 events), followed by child to parent 
(ten) and then parent to child (six). In the subset of these 
events where the subsequent carrier was a young child 
(aged <4 years), most children appeared to have acquired 
carriage from a sibling (13 of 16 events) rather than a 
parent (three of 16 events). In 39 households, a completely 
diﬀ erent strain to the index carrier was acquired by a 
subsequent carrier.
There was insuﬃ  cient power to examine the eﬀ ect of 
MenAfriVac on acquisition or loss of group A carriage 
because few group A carriers were identiﬁ ed during the 
cross-sectional studies.11 However, 11 individuals identiﬁ ed 
as group A carriers were vaccinated during the course of 
follow-up and no further group A carriage was detected 
after vaccination (ﬁ gure 3).
Discussion
In 184 households across the African meningitis belt, the 
overall rate of acquisition of meningococci was 2·4% per 
month. Within household transmission was important, 
especially among children aged less than 5 years, who 
were the group most likely to acquire carriage from other 
household members. However, acquisition of carriage 
outside the household was evident from detection of new 
carriers within households without an index carrier and 
from examination of strain types. The average duration 
of carriage was 3·4 months, shorter than is usually found 
in Europe,21 and persistent carriers were uncommon. 
Few previous studies have examined the patterns of 
Individual Household Baseline 
vaccine
status
Visit 0 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
2
3
4
5
5
6
6
7
8
8
9
9
10
0
Vac
0
0
0
0
0
0
0
0
0
0
0
0
Vac
Vac
Vac
Vac
Vac
Vac
Vac
Vac
Vac
Vac
Vac
Figure 3: Follow-up of serogroup A meningococci carriers and MenAfriVac vaccine status
Orange indicates group A carriage, yellow indicates carriage of non-A meningococci, blue indicates no carriage, and grey indicates missing swab. Vac=vaccinated.
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household transmission of meningococci with which our 
ﬁ ndings can be compared.
The strengths of this study are that it was conducted in 
six countries across the African meningitis belt, involved 
both urban and rural populations, included participants 
across the age spectrum, achieved a high follow-up rate, 
and used standardised ﬁ eld and laboratory protocols. 
Thus, the ﬁ ndings are likely to be representative of the 
pattern of transmission of N meningitidis across the 
African meningitis belt. However, it should be noted that 
the households recruited were not evenly balanced 
between countries and survey periods (table 1).
Although common protocols and microbiological 
methods were used across the diﬀ erent study sites, and 
characterisation of Neisseria spp was conﬁ rmed in Oxford 
using DNA samples, there might have been some 
diﬀ erences between laboratories in their ability to detect 
oxidase-positive Gram-negative diplococci. Additionally 
we assumed that carriage of the same strain as the index 
case represented within-household transmission but we 
cannot rule out external acquisition as the strain type 
might also have been circulating in the wider community. 
We also assumed that a newly identiﬁ ed episode of 
carriage represented acquisition. Due to the infrequent 
detection of group A carriage we were unable to 
determine the relative eﬀ ects of vaccination on reducing 
the duration of carriage compared with preventing 
acquisition.26 There was heterogeneity in carriage 
duration, with some long-term carriers identiﬁ ed. Index 
carriers in our study might have been biased towards 
having longer durations because these individuals would 
be more likely to be detected in a cross-sectional study 
than those with shorter duration of carriers; we were not 
able to adjust for this in our statistical model.
We have reported previously that the prevalence of 
carriage detected during cross-sectional surveys in African 
meningitis belt countries is generally lower than in high-
income countries.11 Although this might reﬂ ect a lower 
incidence of infection (perhaps predisposing to epidemics), 
the short duration of carriage identiﬁ ed in this study, and 
in the only other previous study of carriage duration in 
Africa,18 will also aﬀ ect prevalence. Why the duration of 
carriage would be less in the African meningitis belt than 
in high-income countries is uncertain. This ﬁ nding could 
be a reﬂ ection of a higher background level of immunity, 
although this hypothesis would not ﬁ t with a predisposition 
to epidemics. An alternative explanation is inhibition by 
other bacteria present in the nasopharynx, and it is of note 
that the shortest duration of carriage in the MenAfriCar 
consortium study was in children younger than 5 years 
among whom carriage of N lactamica was highest.27,28 
N lactamica has recently been shown to inhibit colonisation 
with N meningitidis in young adults.29 Another striking 
diﬀ erence in carriage is that there is a similar prevalence 
in children and young adults in Africa11 compared with 
marked peaks in older teenagers and adults in high-
income countries.3
 Widespread deployment of MenAfriVac has, so far, 
proved highly successful in suppressing outbreaks of 
epidemics caused by serogroup A meningococci. 
However, outbreaks due to other serogroups continue to 
occur, with the most recent example being the 2015 
epidemic of serogroup C disease in Niger.9 Until an 
aﬀ ordable multivalent vaccine is available, other control 
measures will be needed. Our ﬁ ndings indicate that 
substantial spread of meningococci occurs within 
households so that prophylaxis of household contacts 
after a case of meningococcal meningitis, recommended 
policy in the meningitis belt outside epidemics,30 could 
be given greater priority. However, given that acquisition 
of infection from outside of the household also occurs, 
vaccination of the whole population of aﬀ ected 
communities will be needed to prevent transmission 
completely and the ﬁ ndings from this study will help to 
guide decisions on the age groups who should be given 
priority.
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